Frontiers in antibiotics最新文献

{"title":"Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.","authors":"Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, Sophia B Georghiou, Norbert Heinrich, Norbert Hittel, Sami Taghlabi, Danna Carrero Longlax, Mikashmi Kohli, Ursula Panzner, Collins Musia, Christoph Lange, Anca Vasiliu, Rob J W Arts, Anna M Mandalakas, Morten Ruhwald, Lieven J Stuyver, Reinout van Crevel","doi":"10.3389/frabi.2025.1748877","DOIUrl":"https://doi.org/10.3389/frabi.2025.1748877","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/frabi.2025.1570989.].</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1748877"},"PeriodicalIF":0.0,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond antibiotics: the expanding horizon of microbial natural products.","authors":"Suchitra Ku Panigrahy, Amrita Kumari Panda, Aseem Kerketa, Rojita Mishra","doi":"10.3389/frabi.2026.1768331","DOIUrl":"10.3389/frabi.2026.1768331","url":null,"abstract":"<p><p>The continuous use of antibiotics has led to the development of antibiotic resistance among bacterial pathogens, posing a significant threat to both human and animal health. This necessitates exploring alternative solutions to combat this growing resistance. Natural products offer a viable alternative for microbial modulation, exhibiting diverse antibacterial processes and the capacity to modify microbial communities and biofilms. These compounds show potential as supplementary agents against resistant infections. Natural products derived from microbes are utilized as biofertilizers and biopesticides, enhancing crop yield and controlling plant pathogens, thereby offering an eco-friendly alternative to chemical fertilizers. Antimicrobial peptides (AMPs) are crucial for combating fish-associated pathogens, reducing mortality rates in the aquaculture industry. Various bacteriocins, are used as food preservatives to inhibit spoilage and pathogenic microorganisms proving their potential in the food industry. In this review, the potential role of natural products from microbes in the food, agriculture, and aquaculture industry sectors has been elucidated. The challenges and prospects were also discussed to provide a foundation for identifying new research opportunities.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1768331"},"PeriodicalIF":3.9,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Emerging trends in phage therapeutics to overcome antibiotic resistance.","authors":"William Calero-Cáceres, Ankush Gupta, Anju Kaushal, Paul Hyman","doi":"10.3389/frabi.2026.1788766","DOIUrl":"10.3389/frabi.2026.1788766","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1788766"},"PeriodicalIF":3.9,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming <i>Candida</i> biofilm resistance: targeting persister cells with probiotic-derived metabolites.","authors":"Priyanka Debta, Binaya Krushna Sahu, Sudipta Kumar Patra, Fakir Mohan Debta, Ekagrata Mishra, Sujogya Kumar Panda","doi":"10.3389/frabi.2026.1767028","DOIUrl":"10.3389/frabi.2026.1767028","url":null,"abstract":"<p><p><i>Candida</i> biofilms pose a significant complication in clinical settings due to antifungal drug tolerance and the presence of persister cells. Biofilm-mediated resistance is influenced by several associated factors, including the high density and extracellular matrix characteristics of the biofilm, metabolic downregulation, efflux pump activity, and stress-response signaling pathways, which ultimately diminish drug permeability and effectiveness. Within biofilms, persister cells form a small subpopulation of cells with unique phenotypic traits that enable them to survive lethal antifungal exposure and promote the recurrence of infection. Failure of antifungal treatments in eliminating biofilm and their resilient communities suggests a need for new, adjunct treatment options Recent findings have highlighted the therapeutic potential of probiotic-derived metabolites for inhibiting certain aspects of biofilm behavior and survival. These postbiotic compounds could offer a multi-faceted, low-toxicity treatment approach that may be used as an adjunct with existing antifungal therapies. Future investigations incorporating mechanistic studies, biofilm models, and drug product development for metabolite formulations could lead to a new treatment strategy for persistent <i>Candida</i> infections.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1767028"},"PeriodicalIF":3.9,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Phage biobanks as enabling infrastructure for precision phage therapy in the era of antimicrobial resistance.","authors":"Paulina Topa-Pila, Katheryne Y Morales, Doménica P Palacios-Mora, Cristina Flores-Hernández, Analía Altamirano-Cisneros, Joselyn Micaela Gavilanes, Keyla Villacís-López, Mirari Arancibia, Johanna Mora-Domínguez, William Calero-Cáceres","doi":"10.3389/frabi.2026.1804100","DOIUrl":"10.3389/frabi.2026.1804100","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/frabi.2026.1772871.].</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1804100"},"PeriodicalIF":0.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12933344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147312676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural product based approaches to overcome <i>Candida glabrata</i> and emerging AMR threats.","authors":"Binaya Krushna Sahu, Sudipta Kumar Patra, Mahesh Chandra Sahu, Sujogya Kumar Panda","doi":"10.3389/frabi.2026.1767032","DOIUrl":"10.3389/frabi.2026.1767032","url":null,"abstract":"<p><p>The rise of <i>C. glabrata</i> as a serious, multidrug-resistant organism poses a significant and global challenge to the human health. The reasons <i>C. glabrata</i> has developed resistance to standard antifungal drugs, include the activation of efflux pumps, the production of biofilms, and changes in ergosterol biosynthesis. In light of the threat posed by <i>C. glabrata</i>, the potential of phytochemicals as therapeutic alternatives should be considered due to their diverse structures and ability to exhibit more than one type of antifungal activity. This review summarizes advances in the use of plant-based natural products displaying antifungal activity against <i>C. glabrata</i>, with an emphasis on key classes of phytochemicals, including flavonoids, terpenoids, phenolic compounds, alkaloids, and essential oils. While the proposed mechanisms include disruption of cell membranes, inhibition of ergosterol synthesis, attenuation of oxidative stress, and suppression of virulence and biofilm formation, it is important to note that most evidence arises from <i>in vitro</i> studies, with only limited mechanistic investigations on individual compounds. Although <i>in vitro</i> studies indicate promising antifungal and adjunctive effects, the available evidence remains largely preclinical, with variable synergistic outcomes. Such synergy not only enhances therapeutic efficacy but also reduces required drug dosages, thereby minimizing toxicity and delaying the emergence of resistance. Major limitations include inconsistency in phytochemical composition, insufficient pharmacokinetic data, and a lack of robust <i>in vivo</i> and clinical studies. This review critically integrates current knowledge, highlighting both the multi-target potential of phytochemicals against <i>C. glabrata</i> and the key challenges that must be addressed to enable realistic clinical translation. By prioritizing synergy-focused research, and methodological standardization, phytocompounds can be positioned not merely as standalone agents but as adjunctive modulators of antifungal resistance, paving the way for novel, effective, and sustainable therapeutic options against MDR <i>C. glabrata</i>.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1767032"},"PeriodicalIF":3.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12930641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phage biobanks as enabling infrastructure for precision phage therapy in the era of antimicrobial resistance.","authors":"Paulina Topa-Pila, Katheryne Y Morales, Doménica P Palacios-Mora, Cristina Flores-Hernández, Analía Altamirano-Cisneros, Joselyn Micaela Gavilanes, Keyla Villacís-López, Mirari Arancibia, Johanna Mora-Domínguez, William Calero-Cáceres","doi":"10.3389/frabi.2026.1772871","DOIUrl":"10.3389/frabi.2026.1772871","url":null,"abstract":"<p><p>The renewed interest in bacteriophage therapy as a response to antimicrobial resistance (AMR) has exposed a critical barrier to its scalable implementation: the lack of structured infrastructure to support precision phage deployment. Due to their narrow host specificity, bacteriophages require timely access to well-matched candidates, making <i>ad hoc</i> isolation and informal exchange insufficient for routine therapeutic use. In this Perspective, we argue that phage biobanks must be redefined as enabling infrastructure rather than passive repositories. We propose that next-generation phage biobanks should integrate curated biological diversity, systematic genomic and functional qualification, and predictive capacity to support rapid phage-host matching. Together, these elements transform biobanks into decision-support systems capable of informing translational applications under time-sensitive conditions. This infrastructural model is particularly relevant within a One Health framework, where resistant pathogens circulate across human, veterinary, agricultural, and environmental domains. Rather than reviewing methodologies, we outline conceptual principles to guide the design of phage biobanks as integrated, predictive, and sustainable assets. We contend that the future impact of phage therapy will depend less on individual phage discovery than on the development of interoperable biobank infrastructures that enable precision antimicrobial interventions at scale.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1772871"},"PeriodicalIF":3.9,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12933349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activity of Biocidin^® against microbial biofilms.","authors":"Amy V Mundanchira, Agnes Wong, Kristen Klos-Maki, Jocelyn Strand, Cláudia N H Marques","doi":"10.3389/frabi.2025.1692653","DOIUrl":"10.3389/frabi.2025.1692653","url":null,"abstract":"<p><p>Biofilms-microbial communities-are present throughout the environment and interact with humans as part of the resident microbiome or when causing infection and disease. Antibiotics are commonly used to treat bacterial infections, including those due to biofilms. However, antimicrobial tolerance and resistance are common traits of these microbial communities. Resistance to antimicrobials is now widespread, and the search for alternative treatments, such as plant- or herbal-derived extracts, essential oils, and honey, is on the rise. Here, we investigated the effect of Biocidin^®, a botanical supplement, on biofilms of <i>Escherichia coli</i>, <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, and <i>Candida albicans</i>. A single (bolus) dose of Biocidin^® resulted in a significant decrease (> 2 Log) of biofilm and planktonic populations, while a 24-h continuous dose of 25% and 50% Biocidin^® led to a typical biphasic killing curve, with the latter concentration resulting in biofilm eradication of <i>P. aeruginosa</i>, <i>S. aureus</i>, and <i>E. coli</i>. Exposure to sub-inhibitory concentrations of Biocidin^® did not affect biofilm viability. Results from this work have implications for the use of Biocidin^® as a treatment for biofilm-associated infections and as a supplement in natural medicine.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1692653"},"PeriodicalIF":0.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12891082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of antimicrobial resistance in Indian healthcare system: combating antimicrobial resistance with precision medicine.","authors":"Ashish Shinde, Athira Mohan, Vani Mahathi Bulusu, Poonam Soni, Jitendra Singh, Sagar Khadanga, Ankur Joshi, Poongothai Venkatachalapathy, Rupinder Kaur Kanwar, Sonal Sekhar Miraj, Murali Munisamy","doi":"10.3389/frabi.2026.1632790","DOIUrl":"10.3389/frabi.2026.1632790","url":null,"abstract":"<p><p>This review provides a unique perspective by integrating antimicrobial resistance (AMR) data from Indian healthcare, with a particular emphasis on outpatient settings that are often overlooked in existing literature. Unlike previous reviews that primarily focus on hospital-acquired infections, this article explores the community dimension of AMR and its implications for public health. Furthermore, it introduces an innovative framework linking AMR mitigation strategies with precision medicine approaches, including pharmacogenomics, metabolomics, proteomics, and transcriptomics. By combining multi-omics insights with national surveillance data and stewardship initiatives, this review highlights the translational potential of personalized antimicrobial therapy tailored to the Indian healthcare ecosystem. This integrated perspective offers a novel direction for AMR research and policy, bridging the gap between genomic science and clinical application in resource-limited settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1632790"},"PeriodicalIF":0.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12891089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial resistance and real-time PCR detection of <i>blaKPC</i> in <i>Klebsiella pneumoniae</i> isolated from wound infections in a tertiary care hospital.","authors":"Bader S Alotaibi, Farkhanda Syed, Fawaz M Almufarriji, Bilal Ahmad Tantry","doi":"10.3389/frabi.2025.1700157","DOIUrl":"10.3389/frabi.2025.1700157","url":null,"abstract":"<p><strong>Background: </strong><i>Klebsiella pneumoniae</i> is a common Gram-negative bacterium frequently associated with wound infections. A major public health concern is the emergence of carbapenem-resistant strains, particularly those carrying the <i>blaKPC</i> gene. This study aimed to detect the <i>blaKPC</i> gene and to determine the antibiotic resistance patterns of <i>K. pneumoniae</i> isolates obtained from wound specimens in a tertiary care hospital in North India.</p><p><strong>Methods: </strong>A total of 1,080 wound swab specimens were collected between October 2023 and September 2024. The isolates were identified as <i>K. pneumoniae</i> using the VITEK-2 identification system and standard biochemical tests. Antimicrobial susceptibility was determined with the Kirby-Bauer disk diffusion method and broth microdilution, interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Carbapenemase production was assessed using the modified Hodge test. Real-time quantitative PCR (qPCR), with 16S rRNA as the internal control, was employed to detect the <i>blaKPC</i> gene in isolates resistant to meropenem.</p><p><strong>Results: </strong>Out of 560 K<i>. pneumoniae</i> isolates, 110 (19.6%) were resistant to meropenem. These resistant isolates also displayed high rates of multidrug resistance, with over 90% resistant to amikacin, ceftazidime, ampicillin, and cefazolin. The qPCR assay revealed that all 110 meropenem-resistant isolates carried the <i>blaKPC</i> gene, with PCR cycle threshold (<i>C</i> _t) values ranging from 12 to 32. No amplification was observed in the meropenem-sensitive negative controls. The diagnostic performance of the qPCR assay demonstrated an area under the curve (AUC) of 0.99, confirming its high accuracy as a diagnostic tool. Furthermore, 83.6% of the isolates harboring the <i>blaKPC</i> gene.</p><p><strong>Conclusion: </strong>In conclusion, <i>K. pneumoniae</i> isolates exhibit a concerning rate of carbapenem resistance mediated by the <i>blaKPC</i> gene. Antimicrobial stewardship and molecular surveillance are crucial for the prevention of the spread of carbapenem-resistant <i>K. pneumoniae</i> in clinical settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1700157"},"PeriodicalIF":0.0,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12888029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}